🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

#PALMERES-2 🇮🇹 real world efficacy study of 1st L CDK4/6 Ribo & abema showed ⬆️ rwPFS in premeno and luminal B disease and overall all pts All 3 showed 🟰 rwPFS in older & bone only pts Hmmm...again suggests palbo isn't really the same #ASCO24 #bcsm

Very nice discussion by Javier Cortes MD PhD suggesting: If someone went to upfront surgery (thinking they had a small tumor) for TNBC + ends up with stage 2/3 TNBC, he would recommend adding carbo to A+T chemo but would not use IO in a pure adj setting OncoAlert

So many powerhouses in one picture! #ASCO24 you were great once again! OncoAlert

Dear Colleagues Our friends/Collaborators at@high5md invite you to watch their international experts reporting the TOP in oncology from #ASCO24 🇺🇸 and beyond Link: high5oncology.tv/meeting-covera…

Fantastic #ASCO24 great connecting again. Hope everyone got home safe. See you all at #ESMO in Barcelona #OncoAlert

Transgender individuals face an elevated risk of cancer in comparison with the general population. There is an urgent need to overcome barriers and enhance cancer prevention and care. bmjoncology.bmj.com/content/3/1/e0…

Couldn’t agree more. Fantastic work by #myriamChalabi and colleagues #Oncoalert

Dear Colleagues, The ESMO - Eur. Oncology Presidential Elections are going on LAST Day to VOTE is June 10th (noon CET) REMINDER THAT ALL VOTES ARE CONFIDENTIAL & NO ONE CAN SEE WHO YOU VOTE FOR esmo.org/about-esmo/how… Election Security is something ESMO takes very seriously to have a FAIR

🚀Don’t miss out on this must-read review on the role of genomic tests in guiding adjuvant ET for #breastcancer. 🌟Stay ahead with the latest insights on this hot topic!

Dose/Exposure Relationship of Exercise and Distant Recurrence in Primary Breast Cancer | Journal of Clinical Oncology ascopubs.org/doi/10.1200/JC… New CANTO data out! Davide Soldato Lee Jones, @GroupeUnicancer FabriceAndre Antonio Di Meglio, MD, PhD Martina Pagliuca Franzoi Maria Alice Gustave Roussy Cancer Survivorship Group

Oggi 13 maggio ⌚️ alle ore 14.00 I Laboratori dell’Oncologia di Domani: Molecular Tumor Board Un Live Webinar con Responsabili Scientifici Proff. Alessandra Gennari e Valentina Guarneri. Programma ed iscrizioni: overgroup.eu/evento/i-labor… #MTB Alessandra Gennari MD PhD

Just released the 2nd version of the ESMO - Eur. Oncology Essentials for Clinicians - Breast Cancer. Honoured to have contributed w a chapter purely focused on BC in #young women. Thanks to Matteo Lambertini, MD PhD for this opportunity and to ESMO - Eur. Oncology editorial team for this effort! OncoAlert

Our Collaborators at high5md are here in San Antonio bringing you LIVE Reports from #SABCS24 🇺🇸from TOP international Experts🌐in #BreastCancer Find their Coverage here: high5oncology.tv/meeting-covera… Experts include Hope Rugo G Curigliano MD PhD Nadia Harbeck,MD PhD Alessandra Gennari MD PhD Sara Tolaney and many

T-DXd approval finally expanded also in Europe to patients with HR+/HER2-0 (ultralow) disease or chemo-naive pts. Appealing post-ET option for patients with aggressive disease course. Congrats G Curigliano MD PhD for leading the DB06 trial that backed this approval! astrazeneca.com/media-centre/p…

Important analyses. Thinking about treatment selection by actual prognosis/risk, and not by study eligibility, is a long standing approach in breast cancer. As was discussed SGBCC St Gallen last month, it should be applied to decision making in adjuvant CDK46i selection, too.

📣ESMO Living Guidelines on Metastatic Breast Cancer: 👉Just updated with the latest recommendations and algorithms in an interactive format. 🔗ow.ly/loX750VBoN6 #ClinicalPracticeGuideline

NEWS FROM INDUSTRY Source AstraZeneca astrazeneca.com/media-centre/p… The Phase III DESTINY-Breast09 trial marks a significant advancement in HER2-positive metastatic #BreastCancer treatment, showing that trastuzumab deruxtecan combined with pertuzumab delivers a statistically

SERENA6 presentation by Nick Turner. What it shows: that a switch to camizestrant/CDKi vs continuing AI/CDKi can keep pts on 1L treatment for 6.9 months longer. What it does not show (yet): that this strategy improves long term outcomes. NEJM publocation: nejm.org/doi/full/10.10…

Da oggi al 14 con AIOM Fondazione Aiom Fondazione AIRC per la ricerca sul cancro SIRM saremo al Porto Antico del COMUNE DI GENOVA per parlare di #prevenzione in oncologia in occasione dell'arrivo del Tour Vespucci Lucia Del Mastro Matteo Lambertini, MD PhD Carlo Genova Francesca Poggio Davide Soldato Andrea Boutros Università di Genova

AIOM Fondazione Aiom Fondazione AIRC per la ricerca sul cancro SIRM COMUNE DI GENOVA Tour Vespucci Lucia Del Mastro Matteo Lambertini, MD PhD Carlo Genova Francesca Poggio Davide Soldato Andrea Boutros Università di Genova Lucrezia Barcellini Beatrice Ramella Pollone Luca Lucente Silvia Puglisi Annalice Gandini Luca Arecco, MD